FORT COLLINS, Colo.--(BUSINESS WIRE)--Ventria Bioscience has announced that Randy Semadeni, who serves as the company’s vice president of business development, will give a podium presentation at the XIth International Conference on Lactoferrin: Structure, Function, and Applications, which begins today in Rome, Italy. The presentation, titled “Enabling Technology for Cost Effective Recombinant Human Lactoferrin,” is scheduled for Tuesday, October 8, 2013 beginning at 4:30 pm Central European Time (UTC+01:00).
“Human lactoferrin has shown many potential therapeutic benefits for human health, but to address these opportunities will require the production of substantial amounts of this protein,” said Mr. Semadeni. “Our presentation will review data and findings from Ventria Bioscience’s experience producing recombinant human lactoferrin in a cost-effective, high-yield manner suitable for cGMP clinical applications, using ExpressTec technology.”
Lactoferrin is an iron-binding glycoprotein found in human breast milk. It is believed to promote healthy establishment of the infant gastrointestinal system and has multiple anti-inflammatory and antimicrobial properties that could potentially be harnessed for therapeutic use. However, the endogenous human form is by its nature extraordinarily difficult to source. Ventria Bioscience has been successful in producing high yields of recombinant human lactoferrin using the company’s proprietary ExpressTec technology platform, and is investigating its therapeutic potential in a number of clinical applications including antibiotic-associated diarrhea, chemotherapy-induced diarrhea, unexplained anemia, inflammatory bowel disease and osteoporosis.
About the Conference
The objective of the International Conference on Lactoferrin: Structure, Function, and Applications is to “provide a forum for discussions to promote research and publication on the benefits of lactoferrin as a mediator of general health and wellness and on its potential therapeutic applications.” The conference is organized by an international committee and held biannually. A full program for this year’s conference is available at http://www.lactoferrinconference.com/program.
About Ventria Bioscience
Ventria Bioscience develops, manufactures, and markets biotherapeutics and bioreagents. Ventria Bioscience’s patented ExpressTec biomanufacturing technology enables the development of new and cost-effective biologic products. For more information, visit www.Ventria.com.
